close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

26.01 -1.13 (-4.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
If You Invested $100 In This Stock 5 Years Ago, You Would Have $800 Today
 
Via Benzinga
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3... 
Via Benzinga
Breaking Down Moderna: 7 Analysts Share Their Views
 
Via Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
Via ACCESSWIRE
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Via ACCESSWIRE
Why Moderna Stock Is Sinking This Week
Moderna's sell-off this week is for the birds. 
Via The Motley Fool
Is Moderna Stock a Buy Now That It's a 2-Product Company?
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. 
Via The Motley Fool
Moderna Investors Just Got Some Bullish News
This news could be worth billions... 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
FDA approves Moderna's mRESVIA (mRNA-1345), an mRNA vaccine for RSV, for adults 60+. The second approved mRNA product from Moderna. 
Via Benzinga
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years. 
Via Investor's Business Daily
Moderna's Options Frenzy: What You Need to Know
 
Via Benzinga
3 Sorry Biotech Stocks to Sell in May While You Still Can
Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell. 
Via InvestorPlace
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
Moderna Pops After Confirming The U.S. Government Could Back Its Bird Flu Vaccine
The company expects to have data soon from its Phase 1 and Phase 2 study of a bird flu vaccine. 
Via Investor's Business Daily
3 Nasdaq Stocks to Dump as They Near Peak Performance
Moderna, Constellation Energy and CrowdStrike are three Nasdaq stocks to sell, each offering unique exit points in a peaking market. 
Via InvestorPlace
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir 
Via Benzinga
VIX Rises 8%, Treasury Yields Jump, Dow Plunges: Why Is Wall Street Wobbling Thursday?
Wall Street opens with red showing as investors worry about interest rates. Volatility and Treasury yields spike. Traders expect 1-2 rate cuts. 
Via Benzinga
Topics Stocks
3 Sorry Pharma Stocks to Sell in May While You Still Can
Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy. 
Via InvestorPlace
Cathie Wood's Ark Invest Scoops Up Shares Of AMD And Palantir — Dumps Moderna Stock Worth $4.4M
 
Via Benzinga
What's Going On With Moderna Stock Today?
Moderna Inc. (NASDAQ: MRNA) shares are trading lower Tuesday. The stock may be pulling back after gaining on bird flu concerns last week and predictions for a slight rise in COVID-19 cases. 
Via Benzinga
US Stocks Waver, Nvidia Lifts Chipmakers, GameStop Spikes, Moderna Tumbles: What's Driving Markets Tuesday?
Wall Street resumed trading after the Memorial Day holiday with a familiar trend, as major chipmaker stocks significantly outperformed the broader market. 
Via Benzinga
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock,
Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter financial results. 
Via Benzinga
Moderna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?
Top-performing stocks last week were FSLR, MRNA, ELF, NVDA, IP, ADI, FLEX, LOGI, BNTX, and MNDY, boosted by positive news and analyst targets. 
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Should You Buy This Stock After a Regulatory Setback?
It's not uncommon for companies to face regulatory setbacks -- and It's not the end of the world. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely? 
Via The Motley Fool
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today